Key Quantitative Figures

Financial Performance (Standalone - Amount in Lakhs):

  • Revenue from business operations: ₹0.00 (Previous year: ₹0.00)
  • Other Income: ₹6.69 (Previous year: ₹18.12)
  • Total Income: ₹6.69 (Previous year: ₹18.12)
  • Operating profit before depreciation, finance cost, exceptional items and tax (EBITDA): ₹(5.99) (Previous year: ₹7.62)
  • Depreciation & Amortization: ₹0.01 (Previous year: ₹0.02)
  • Finance Cost: ₹0.00 (Previous year: ₹0.00)
  • Profit before tax: ₹(6.00) (Previous year: ₹7.60)
  • Current Tax: ₹0.00 (Previous year: ₹1.63)
  • Deferred Tax: ₹0.03 (Previous year: ₹0.00)
  • Net Profit for the year: ₹(6.04) (Previous year: ₹5.97)
  • Other Comprehensive Income: ₹(16.65) (Previous year: ₹(34.70))
  • Total Comprehensive Income: ₹(22.69) (Previous year: ₹(28.73))
  • Paid-up equity share capital: ₹191.50 (Previous year: ₹191.50)
  • EPS (Basic & Diluted): ₹(1.18) (Previous year: ₹1.50)

Financial Performance (Consolidated - Amount in Lakhs):

  • Revenue from business operations: ₹709.78 (Previous year: ₹705.18)
  • Other Income: ₹30.60 (Previous year: ₹38.27)
  • Total Income: ₹740.38 (Previous year: ₹743.45)
  • Operating profit before depreciation, finance cost, exceptional items and tax (EBITDA): ₹(116.68) (Previous year: ₹(187.15))
  • Depreciation & Amortization: ₹47.86 (Previous year: ₹54.20)
  • Finance Cost: ₹2.11 (Previous year: ₹1.20)
  • Profit before tax: ₹(166.66) (Previous year: ₹(242.55))
  • Current Tax: ₹0.00 (Previous year: ₹1.63)
  • Deferred Tax: ₹(54.98) (Previous year: ₹(7.29))
  • Net Profit for the year: ₹(111.68) (Previous year: ₹(236.89))
  • Other Comprehensive Income: ₹(16.65) (Previous year: ₹(34.70))
  • Total Comprehensive Income: ₹(128.33) (Previous year: ₹(271.59))
  • Paid-up equity share capital: ₹191.50 (Previous year: ₹191.50)
  • EPS (Basic & Diluted): ₹(6.70) (Previous year: ₹(14.18))

Subsidiary Performance:

Skybiotech Life Sciences Private Limited reported total income of ₹709.78 lakhs and total expenditure of ₹894.35 lakhs, resulting in loss of ₹105.65 lakhs for FY 2024-25.

Dates of Action

  • Annual Report submission date: 05/09/2026
  • 43rd Annual General Meeting date: 30/09/2026 at 11:00 AM
  • Remote e-voting period: 26/09/2026 at 10:00 AM to 29/09/2026 at 05:00 PM
  • Cut-off date for voting rights: 23/09/2026
  • Board meetings held during FY 2025-26: 30.05.2025, 24.06.2025, 14.08.2025, 28.08.2025, 14.11.2025, 14.02.2026, 30.03.2026

Parties Involved

Board of Directors:

  • Mr. Prakashchandra Rathi (Director and CFO, DIN: 01393087)
  • Mrs. Poonam Prakash Rathi (Managing Director, DIN: 01274428)
  • Yogesh Nandlal Chandak (Independent Director)
  • Mr. Rakesh Somani (Independent Director)
  • Mr. Jagdish Mantri (Independent Director)
  • Mr. Vijay Sitaram Chitlange (Independent Director, appointed 28/08/2025)

Key Managerial Personnel:

  • CS Nishi Jain (Company Secretary & Compliance Officer)
  • Mr. Prakashchandra Rathi (CFO)

Statutory Auditors:

M/s. SPD and Associates, Chartered Accountants (FRN: 139118W)

Secretarial Auditor:

M/s. SM Dhumal and Associates, Company Secretaries

Share Transfer Agent:

M/s. Satellite Corporate Services Pvt. Ltd.

Business Changes and Rationale

Change in Nature of Business:

The company changed its business object from manufacturing and trading of textile products to manufacturing and trading of pharmaceutical products, nutraceuticals, and healthcare preparations. The rationale provided was that the company was not able to generate revenue from textile operations and is now in process of acquiring registrations and licenses required for pharma business.

Share Capital Changes:

Increased authorized share capital from ₹2,00,00,000 divided into 20,00,000 equity shares of ₹10 each to ₹5,00,00,000 divided into 50,00,000 equity shares of ₹10 each through special resolution passed in AGM dated September 25, 2025.

Paid-up equity share capital remains unchanged at ₹191.50 lakhs comprising 19,15,000 equity shares of ₹10 each.

Material Investments and Transactions

  • Investment of ₹10 crores in equity shares of Skybiotech Life Science Private Limited (68,80,746 equity shares of ₹10 each)
  • Related party transactions include loans taken from directors: Prakashchandra Rathi (₹3,98,436), Poonam Rathi (₹4,00,000), and Skybiotech Life Sciences Pvt Ltd (₹7,35,085)

AGM Agenda Items

Ordinary Business:

1. Adoption of Audited Standalone Financial Statements for FY ended March 31, 2026

2. Adoption of Audited Consolidated Financial Statements for FY ended March 31, 2026

3. Re-appointment of Mr. Prakashchandra Rathi (DIN: 01393087) as director retiring by rotation

4. Appointment of M/s. SPD & Associates, Chartered Accountants (FRN: 139118W) as statutory auditors for 5 years until conclusion of 48th AGM

Corporate Governance Structure

Board Committees:

Audit Committee:

  • Rakesh Ramswaroop Somani (Chairperson, Independent Director)
  • Jagdish Manohar Mantri (Member, Independent Director)
  • Poonam Prakash Rathi (Member, Managing Director)

Stakeholder Relationship Committee:

  • Rakesh Ramswaroop Somani (Chairperson, Independent Director)
  • Jagdish Manohar Mantri (Member, Independent Director)
  • Poonam Prakash Rathi (Member, Managing Director)

Nomination and Remuneration Committee:

  • Rakesh Ramswaroop Somani (Chairperson, Independent Director)
  • Jagdish Manohar Mantri (Member, Independent Director)
  • Poonam Prakash Rathi (Member, Managing Director)

Dividend and Reserves

No dividend declared for FY 2025-26. No amount transferred to General Reserve.

Internal Financial Controls

Company maintains adequate internal financial controls system which were operating effectively as at March 31, 2026 based on internal control over financial reporting criteria.

Secretarial Audit Observations

1. Form DIR-12 not filed for resignation of CS Swati Maheshwari (01/10/2024)

2. Form INC-22 not filed for shifting of registered office (special resolution passed 21/11/2023)

3. Mr. Yogesh Nandlal Chandak completed tenure of ten years as Independent Director but still acting as director

4. Website maintenance issues during the year (now resolved)

Going Concern Status

No significant or material order passed by any regulator, court or tribunal impacting the going concern status of the Company.

Subsidiary Information

Skybiotech Life Sciences Private Limited (72.52% holding) is the only subsidiary company.

#Tags: #SkybiotechHealthcare #AnnualReport #SEBIDisclosure #RegulatoryCompliance #FinancialResults #AGMNotice #Pharmaceuticals #BusinessTransition